First identified in Japan in 2009, the fungus has reportedly reached at least 60 countries and dozens of US states

A deadly, drug-resistant fungus already spreading rapidly through U.S. hospitals is becoming even more threatening worldwide, though there may be hope for new treatments, according to a new scientific review.

Candida auris (C. auris), often described as a “superbug fungus,” is spreading globally and increasingly resisting human immune systems, Hackensack Meridian Center for Discovery and Innovation (CDI) researchers said in a review published in early December.

The findings reinforce prior CDC warnings that have labeled C. auris an “urgent antimicrobial threat” — the first fungal pathogen to receive that designation — as U.S. cases have surged, particularly in hospitals and long-term care centers.

Approximately 7,000 cases were identified across dozens of U.S. states in 2025, according to the CDC, and it has reportedly been identified in at least 60 countries.

The review, published in Microbiology and Molecular Biology Reviews, helps explain why the pathogen is so difficult to contain and warns that outdated diagnostics and limited treatments lag behind. It was conducted by Dr. Neeraj Chauhan of the Hackensack Meridian CDI in New Jersey, Dr. Anuradha Chowdhary of the University of Delhi’s Medical Mycology Unit and Dr. Michail Lionakis, chief of the clinical mycology program at the National Institutes of Health.

Their findings stress the need to develop “novel antifungal agents with broad-spectrum activity against human fungal pathogens, to improve diagnostic tests and to develop immune- and vaccine-based adjunct modalities for the treatment of high-risk patients,” the researchers said in a statement.

Read More Here